PET/CT IN ASSESSING THE LYMPHOMA RESPONSE TO TREATMENT

Yulduzkhan Dauytova, Zhamilya Zholdybay, Zh. Zhakenova, J. Amankulov, S. Baigulova
{"title":"PET/CT IN ASSESSING THE LYMPHOMA RESPONSE \nTO TREATMENT","authors":"Yulduzkhan Dauytova, Zhamilya Zholdybay, Zh. Zhakenova, J. Amankulov, S. Baigulova","doi":"10.52532/2521-6414-2022-1-63-32-35","DOIUrl":null,"url":null,"abstract":"Relevance: PET/CT has become an integral part of the diagnostic algorithm in lymphoma patients since lymphomas actively accumulate 18F-FDG. The high accuracy of PET/CT in patients with certain lymphoma types allows effective use of this method in clinical practice \nfor diagnosis, staging, re-staging, evaluating the effectiveness of treatment, and determining further patient management tactics. \nThe study aimed to evaluate the PET/CT capacity in assessing lymphoma treatment effectiveness. \nMethods: We conducted a retrospective analysis of PET/CT 18F-FDG results in 109 patients with a verified lymphoma diagnosis. The \npatients underwent PET/CT examinations at “Orhun Medical” PET/CT center based in the JSC “Kazakh Institute of Oncology and Radiology” (Almaty, Kazakhstan). \nResults: According to PET/CT results in assessing the lymphoma treatment effectiveness, the stabilization of the process was achieved \nin 38.5% of cases, progression – in 33.03%, a partial metabolic response – in 18.35%, and a complete response – in 10.09% of cases. \nConclusion: PET/CT is the method of choice for evaluating the effectiveness of lymphoma treatment compared to other radiological \ntechniques. PET/CT is based on determining metabolic treatment response, not only on size indicators. It plays an essential role in different \nstages of lymphoma treatment, providing new opportunities for personalized treatment","PeriodicalId":19480,"journal":{"name":"Oncologia i radiologia Kazakhstana","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologia i radiologia Kazakhstana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52532/2521-6414-2022-1-63-32-35","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Relevance: PET/CT has become an integral part of the diagnostic algorithm in lymphoma patients since lymphomas actively accumulate 18F-FDG. The high accuracy of PET/CT in patients with certain lymphoma types allows effective use of this method in clinical practice for diagnosis, staging, re-staging, evaluating the effectiveness of treatment, and determining further patient management tactics. The study aimed to evaluate the PET/CT capacity in assessing lymphoma treatment effectiveness. Methods: We conducted a retrospective analysis of PET/CT 18F-FDG results in 109 patients with a verified lymphoma diagnosis. The patients underwent PET/CT examinations at “Orhun Medical” PET/CT center based in the JSC “Kazakh Institute of Oncology and Radiology” (Almaty, Kazakhstan). Results: According to PET/CT results in assessing the lymphoma treatment effectiveness, the stabilization of the process was achieved in 38.5% of cases, progression – in 33.03%, a partial metabolic response – in 18.35%, and a complete response – in 10.09% of cases. Conclusion: PET/CT is the method of choice for evaluating the effectiveness of lymphoma treatment compared to other radiological techniques. PET/CT is based on determining metabolic treatment response, not only on size indicators. It plays an essential role in different stages of lymphoma treatment, providing new opportunities for personalized treatment
Pet / ct评估淋巴瘤对治疗的反应
相关性:由于淋巴瘤主动积累18F-FDG, PET/CT已成为淋巴瘤患者诊断算法中不可或缺的一部分。PET/CT对某些淋巴瘤类型患者的高准确性使得该方法在临床实践中可以有效地用于诊断、分期、再分期、评估治疗效果以及确定进一步的患者管理策略。本研究旨在评估PET/CT在评估淋巴瘤治疗效果方面的能力。方法:我们对109例确诊为淋巴瘤的患者的PET/CT 18F-FDG结果进行回顾性分析。患者在“哈萨克斯坦肿瘤和放射学研究所”JSC(哈萨克斯坦阿拉木图)的“Orhun Medical”PET/CT中心接受了PET/CT检查。结果:根据评估淋巴瘤治疗效果的PET/CT结果,38.5%的病例实现了过程稳定,33.03%的病例实现了进展,18.35%的病例实现了部分代谢缓解,10.09%的病例实现了完全缓解。结论:与其他放射技术相比,PET/CT是评价淋巴瘤治疗效果的首选方法。PET/CT是基于确定代谢治疗反应,而不仅仅是尺寸指标。它在淋巴瘤治疗的不同阶段起着至关重要的作用,为个性化治疗提供了新的机会
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信